This is a working overview of dual agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-07-25. Anything still debated is marked as such rather than presented as settled.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Bragg on X-ray crystallography, "Concerning the Nature of Things", which helped her decide her future. She was further encouraged by the chemist A.F. Joseph, a family friend who also worked in Sudan. Her state school education did not include Latin, then required for entrance to Oxbridge. Her Leman School headmaster, George Watson, gave her personal tuition in the subject, enabling her to pass the University of Oxford entrance examination. When Hodgkin was asked in later life to name her childhood heroes, she named three women: first and foremost, her mother, Molly; the medical missionary Mary Slessor; and Margery Fry, the Principal of Somerville College.
== Shoulder sleeve and insignia == The division's square insignia, is identifiable by an arched red banner embroidered with the letters "AA" (standing for "All American") behind a shade of blue. It serves as the service colors of the United States Army, with red representing artillery and blue for infantry. A white on blue "Airborne" tab is worn above the insignia. "All American" is the nickname given to the division when it was first formed at Camp Gordon, Georgia, in 1917, submitted by Vivienne Goodwyn. The insignia was approved in 1918 during World War I.
The ancestors of coleoids (including most modern cephalopods) and the ancestors of the modern nautilus, had diverged by the Floian Age of the Early Ordovician Period, over 470 million years ago. The Bactritida, a Devonian–Triassic group of orthocones, are widely held to be paraphyletic without the coleoids and ammonoids, that is, the latter groups arose from within the Bactritida. An increase in the diversity of the coleoids and ammonoids is observed around the start of the Devonian period and corresponds with a profound increase in fish diversity. This could represent the origin of the two derived groups. Unlike most modern cephalopods, most ancient varieties had protective shells. These shells at first were conical but later developed into curved nautiloid shapes seen in modern nautilus species. Competitive pressure from fish is thought to have forced the shelled forms into deeper water, which provided an evolutionary pressure towards shell loss and gave rise to the modern coleoids, a change which led to greater metabolic costs associated with the loss of buoyancy, but which allowed them to recolonize shallow waters. However, some of the straight-shelled nautiloids evolved into belemnites. The loss of the shell may also have resulted from evolutionary pressure to increase maneuverability, resulting in a more fish-like habit. There has been debate on the embryological origin of cephalopod appendages. Until the mid-20th century, the "Arms as Head" hypothesis was widely recognized.
=== Innate immunity === Introduction of too many siRNAs can result in nonspecific events due to activation of innate immune responses. Most evidence to date suggests that this is probably due to activation of the dsRNA sensor PKR, although retinoic acid-inducible gene I (RIG-I) may also be involved. The induction of cytokines via toll-like receptor 7 (TLR7) has also been described. Chemical modification of siRNA is employed to reduce the activation of the innate immune response for gene function and therapeutic applications. One promising method of reducing the nonspecific effects is to convert the siRNA into a microRNA. MicroRNAs occur naturally, and by harnessing this endogenous pathway it should be possible to achieve similar gene knockdown at comparatively low concentrations of resulting siRNAs, to minimize nonspecific effects.
The slide shows at (1) an epithelial cell infected by Chlamydia pneumoniae; their inclusion bodies shown at (3); an uninfected cell shown at (2) and (4) showing the difference between an infected cell nucleus and an uninfected cell nucleus. Epithelium grown in culture can be identified by examining its morphological characteristics. Epithelial cells tend to cluster together, and have a "characteristic tight pavement-like appearance". But this is not always the case, such as when the cells are derived from a tumor. In these cases, it is often necessary to use certain biochemical markers to make a positive identification. The intermediate filament proteins in the cytokeratin group are almost exclusively found in epithelial cells, so they are often used for this purpose. Cancers originating from the epithelium are classified as carcinomas. In contrast, sarcomas develop in connective tissue. When epithelial cells or tissues are damaged from cystic fibrosis, sweat glands are also damaged, causing a frosty coating of the skin.
Sources: en.wikipedia.org
==== ESI MS ==== ESI-MS was initially developed by Fenn and colleagues for analysis of biomolecules. It depends on the formation of gaseous ions from polar, thermally labile and mostly non-volatile molecules and thus is completely suitable for a variety of lipids. It is a soft-ionization method that rarely disrupts the chemical nature of the analyte prior to mass analysis. Various ESI-MS methods have been developed for analysis of different classes, subclasses, and individual lipid species from biological extracts. Comprehensive reviews of the methods and their application have recently been published. The major advantages of ESI-MS are high accuracy, sensitivity, reproducibility, and the applicability of the technique to complex solutions without prior derivatization. Han and coworkers have developed a method known as"shotgun lipidomics" which involves direct infusion of a crude lipid extract into an ESI source optimized for intrasource separation of lipids based on their intrinsic electrical properties.
Many of his reports, which he wrote primarily for the newspaper Frankfurter Allgemeine Zeitung, the news magazine Der Spiegel and the weekly newspaper Die Zeit, were also published in expanded versions as books, becoming bestsellers. In cooperation with the Avicenna relief organization founded by his father Djavad Kermani, Kermani initiated fundraising campaigns for aid projects in Aceh (Indonesia), Lesbos, Madagascar and Tigray after returning from his reporting trips. Kermani's books have been translated into numerous languages. In his public statements and speeches, Kermani regularly comments on issues of society, politics and religion. Jan-Werner Müller described him in the New York Review of Books as one of Germany's most thought-provoking intellectual voices. From 2009 to 2012, Kermani was a senior fellow at the Kulturwissenschaftliches Institut (KWI) Institute for Advanced Humanities Study in Essen. In 2009, he was appointed a corresponding member of the Akademie der Wissenschaften [Academy of Sciences] in Hamburg. In the summer semester of 2010, Kermani served as guest lecturer in poetics at the Goethe University Frankfurt, where he gave the Frankfurter Poetikvorlesungen [Frankfurt Poetics Lectures], which were later published as a book entitled Über den Zufall. Jean Paul, Hölderlin und der Roman, den ich schreibe [On Contingency: Jean Paul, Hölderlin, and the Novel I Am Writing]. In the winter semester of 2011/12, Kermani delivered the Göttingen Poetics Lecture series, and in 2014, the Mainz Poetics Lecture series.
Direct-to-consumer blood testing (DTC blood testing), also known as direct access testing (DAT), is a form of laboratory testing that allows consumers to order blood tests directly from a clinical laboratory without requiring a prescription or referral from a physician. This market has grown significantly in recent years, driven by consumer interest in personalized health management, advances in laboratory technology, and regulatory changes that have expanded access in many jurisdictions. These services typically offer comprehensive metabolic panels, lipid profiles, hormone testing, nutritional markers, and increasingly sophisticated biomarker assessments that were traditionally only available through healthcare providers. Over the last decade, a paradigm shift has taken place with consumers seeking greater involvement in decisions affecting their healthcare and with policies that enable this involvement.
After a physician ensures that the patient voluntarily chooses to receive treatment through a consent form, treatment planning can begin. The patient must show current addiction to an opioid, using accepted medical criteria such as those listed in the DSM-5 and have evidence that he or she became addicted at least 1 year before admission for treatment. Before administration of treatment, a clinical evaluation is required asking about drug use history, co-occurring disorders, and impact of substance use on life, along with providing information about the treatment goals and guidelines. A medical evaluation is also given in the form of a urinalysis test, a review of past and current health history, and a test for certain conditions which are known to be prevalent in addict populations, such as HIV, hepatitis, and tuberculosis. The medication is monitored by nursing staff and is prescribed by a physician. As of 2013, due to the strict changes in receiving prescription pain medication as well as decreases in non-medical prescription use, the requirements to be accepted into methadone clinics have changed in areas such as New York State.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.